James Paul Rickey Purchases 27,777 Shares of Braveheart Bio (NASDAQ:BRVE) Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) CFO James Paul Rickey acquired 27,777 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average price of $18.00 per share, with a total value of $499,986.00. Following the completion of the acquisition, the chief financial officer owned 520,927 shares of the company’s stock, valued at $9,376,686. This represents a 5.63% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Braveheart Bio Stock Performance

Shares of Braveheart Bio stock traded up $0.20 during midday trading on Friday, reaching $30.00. 565,846 shares of the company’s stock traded hands. Braveheart Bio, Inc. has a 52 week low of $28.47 and a 52 week high of $32.00.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.